World Psoriasis Day 2026: What Is Psoriasis?

World Psoriasis Day takes place on Thursday, October 29, 2026, and this year’s theme is “Look Beyond My Skin.” The 2026 campaign centers on young people, because nearly one in three adults with psoriasis first developed the condition before turning 18. The theme asks the public to see the person first, not the patches on their skin.

Psoriasis is far more than a cosmetic skin problem. It is a long-term condition driven by the immune system, and it can affect the joints, the heart, and mental health as well as the skin. This article explains what psoriasis is, how it affects the body, how it is treated today, and how clinical research is shaping the next generation of care.

What is World Psoriasis Day, and why does the 2026 theme focus on young people?

World Psoriasis Day is an annual global awareness day held every October 29. It is organized by an international federation of psoriasis patient associations, founded in 1971, which first held the day in 2004. The observance is now marked in more than 70 countries through community events, advocacy campaigns, and public education.

The day carries added weight because of a 2014 milestone. That year, the world’s health ministers, meeting at their annual global health assembly, formally recognized psoriasis as a serious noncommunicable disease, meaning a long-term illness that does not spread from person to person.

The 2026 theme focuses on children, teenagers, and young adults. A visible skin condition during the school years can affect confidence, friendships, and participation in sports and social life. Young people with psoriasis share many experiences with those living with other chronic immune conditions that begin in childhood, including the need for early diagnosis, steady support, and care that considers emotional health alongside physical symptoms.

What is psoriasis, and is it contagious?

Psoriasis is a chronic, immune-mediated disease. In people with psoriasis, the immune system becomes overactive and releases inflammatory chemical messengers, called cytokines, that signal skin cells to grow far too quickly. Healthy skin replaces itself over roughly a month. In psoriasis, new cells reach the surface in just a few days and pile up, forming raised, thickened patches called plaques.

Psoriasis is not contagious. It cannot be caught through touch, shared towels, or swimming pools. It often runs in families, and flares (periods when symptoms worsen) can be set off by stress, infections such as strep throat, skin injuries, cold and dry weather, smoking, heavy alcohol use, and certain medicines. When new patches appear exactly where the skin was scratched or cut, doctors call it the Koebner phenomenon.

In the United States, about three in every hundred adults live with psoriasis, and global estimates place the number well above 100 million people. The condition takes several forms:

Plaque psoriasis is the most common type, accounting for roughly eight or nine in every ten cases. It causes raised, scaly patches, often on the elbows, knees, scalp, and lower back.
Guttate psoriasis appears as many small, drop-shaped spots and often follows a strep throat infection, most commonly in children and young adults.
Inverse psoriasis causes smooth, inflamed patches in skin folds such as the armpits, groin, and the area under the breasts.
Pustular psoriasis is a less common type with bumps filled with pus that are not caused by infection.
Erythrodermic psoriasis is a rare, severe form that inflames most of the body’s skin and requires emergency medical care.

Psoriasis can also affect the nails, causing tiny dents, discoloration, or lifting, and it frequently involves the scalp. Its appearance varies across skin tones. On lighter skin, patches usually look pink or red with silvery-white scale. On brown and Black skin, they often look purple, gray, or dark brown and can leave temporary dark or light marks as they heal. Because many medical reference images still show psoriasis mainly on lighter skin, diagnosis can take longer for people with darker skin tones.

Psoriasis is sometimes confused with eczema, another common inflammatory skin condition. Eczema tends to cause intense itch and often begins in early childhood, while psoriasis typically produces thicker, more sharply outlined patches. A closer look at the signs and triggers of eczema shows how the two differ. A dermatologist (a doctor who specializes in skin) can confirm which condition is present, sometimes with a small skin sample called a biopsy.

How does psoriasis affect the rest of the body?

Because psoriasis is driven by the immune system, its effects reach beyond the skin, which is why specialists increasingly use the term psoriatic disease.

The most common related condition is psoriatic arthritis, an inflammatory arthritis that causes joint pain, swelling, and stiffness. Up to about one in three people with psoriasis develop it, often several years after skin symptoms first appear. Warning signs include morning stiffness, a swollen finger or toe, heel pain, and nail changes. Without treatment, psoriatic arthritis can cause lasting joint damage, which is why recognizing early arthritis symptoms matters for anyone living with psoriasis.

People with psoriasis are also more likely to develop several other conditions, including:

Heart disease and stroke.
Metabolic syndrome, a cluster of conditions that includes high blood pressure, high blood sugar, excess belly fat, and abnormal cholesterol.
Type 2 diabetes.
Depression and anxiety.
Inflammatory bowel disease, such as Crohn’s disease.

A higher risk does not mean these conditions are inevitable. It does mean that regular checkups, including blood pressure, blood sugar, and cholesterol screening, are a sensible part of long-term psoriasis care.

The emotional side of psoriasis carries equal weight. Visible patches can lead to stigma, unwanted comments, and social withdrawal, and a majority of people with psoriasis report that the disease is a significant problem in their everyday lives. This is the experience the 2026 theme seeks to change: being judged by the skin rather than seen as a whole person.

How is psoriasis treated today, and what is new?

There is no cure for psoriasis yet, but many treatments can help control symptoms, and some people experience long stretches of clear or nearly clear skin, known as remission. Treatment choices depend on how much skin is affected, where the patches are, whether the joints are involved, and a person’s overall health. The main treatment categories include:

Topical treatments: creams, ointments, foams, and lotions applied directly to the skin, including steroid creams, vitamin D-based creams, and newer non-steroid options.
Phototherapy: controlled doses of ultraviolet light, given under medical supervision.
Traditional systemic medicines: pills or injections that calm the immune system throughout the whole body.
Oral targeted medicines: pills that block specific inflammatory signals inside cells.
Biologics: medicines made from living cells, given by injection or infusion, that block a single immune messenger involved in psoriasis.

The past two years have brought notable progress. The U.S. Food and Drug Administration (FDA) approved a targeted biologic for some children as young as 6 in 2025, and in 2026 extended a non-steroid cream to children as young as 2. In March 2026, the FDA approved the first once-daily pill designed to block the receptor for IL-23, one of the key immune messengers behind psoriasis, for adults and adolescents. Another oral medicine that works on a related pathway is under FDA review, with a decision expected in early 2027, and remains investigational until then. Lower-cost versions of an established biologic, known as biosimilars, have also become available.

Every one of these options first had to prove itself in clinical trials. Even so, trial results do not guarantee the same response for every person, and how a treatment performs in everyday practice can differ from the controlled conditions of a study. Treatment decisions belong with a dermatologist or primary care clinician who knows the person’s full health history.

How do psoriasis clinical trials work, and who can take part?

Clinical trials are research studies that test whether new treatments are safe and effective. Early phases check safety and dosing in small groups. Later phases compare a new treatment with existing care or a placebo (an inactive look-alike treatment) in hundreds or thousands of people, and post-approval studies continue to monitor long-term safety. Current psoriasis research includes new pills and injections and studies in children.

Psoriasis trials rely on specific measures to decide who can join and to track results. Terms that commonly appear in eligibility criteria include:

Body surface area (BSA): the share of skin covered by psoriasis. One handprint equals roughly 1 percent of the body’s skin.
Psoriasis Area and Severity Index (PASI): a score from 0 to 72 that combines how much skin is affected with how red, thick, and scaly the patches are.
Investigator’s Global Assessment (IGA): a doctor’s overall rating of severity on a scale from 0 (clear) to 4 (severe).
Washout period: a required break from certain current medicines before a study begins, so earlier treatment does not affect the results.

These requirements protect participants and keep results reliable. They also explain why some interested people are screened but still do not qualify.

Representation remains a known gap. Across large late-stage psoriasis trials, the great majority of participants have been white, even though psoriasis affects people of every background. Recent research shows that broad inclusion is achievable when studies are designed for it from the start, and more representative trials help researchers understand how treatments perform across skin tones and ancestries.

Joining a trial is always voluntary. Before taking part, each person goes through informed consent, a process in which the research team explains the study’s purpose, procedures, possible risks, and possible benefits. Participants can withdraw at any time. Trial participation is research, not a guaranteed form of treatment, and it is best discussed with a dermatologist.

DecenTrialz is a clinical trial recruitment and pre-screening platform that helps people find studies that may fit their health profile. Participants share some information about their health, AI-assisted matching identifies relevant trials, and a registered nurse reviews that information before a referral is sent to a research site.

The research site team makes all final eligibility decisions and handles informed consent and enrollment.

Frequently asked questions about psoriasis

Can diet cure psoriasis?

No diet has been shown to cure psoriasis. Eating a balanced diet, maintaining a healthy weight, limiting alcohol, and not smoking may help reduce flares for some people and support heart health, but these steps are not a substitute for medical treatment.

Is psoriasis hereditary?

Genes play an important role, and psoriasis often runs in families. Still, many people with a family history never develop it, because environmental triggers also matter.

Does psoriasis ever go away?

Psoriasis is a chronic condition, but symptoms often come and go. Many people experience periods of remission lasting months or longer, and effective treatment can keep skin clear or nearly clear for extended periods.

When should someone see a doctor about psoriasis?

Anyone with persistent scaly patches, nail changes, or joint pain alongside skin symptoms should see a clinician. Widespread redness across most of the skin, or pus-filled bumps with fever or chills, needs urgent medical care.

Looking beyond the skin

World Psoriasis Day is a reminder that psoriasis is a serious, lifelong immune condition. It is not a sign of poor hygiene, and no one can catch it. Early diagnosis, attention to the joints, heart, and mental health, and a growing range of treatments all help people live well with the disease.

Progress in psoriasis care has come from people who volunteered for clinical research, and future progress depends on studies that reflect the full range of people living with the condition. Those curious about current psoriasis studies can explore options at decentrialz.com and discuss any opportunity with their dermatologist. #LookBeyondMySkin